<code id='CD4316024A'></code><style id='CD4316024A'></style>
    • <acronym id='CD4316024A'></acronym>
      <center id='CD4316024A'><center id='CD4316024A'><tfoot id='CD4316024A'></tfoot></center><abbr id='CD4316024A'><dir id='CD4316024A'><tfoot id='CD4316024A'></tfoot><noframes id='CD4316024A'>

    • <optgroup id='CD4316024A'><strike id='CD4316024A'><sup id='CD4316024A'></sup></strike><code id='CD4316024A'></code></optgroup>
        1. <b id='CD4316024A'><label id='CD4316024A'><select id='CD4316024A'><dt id='CD4316024A'><span id='CD4316024A'></span></dt></select></label></b><u id='CD4316024A'></u>
          <i id='CD4316024A'><strike id='CD4316024A'><tt id='CD4316024A'><pre id='CD4316024A'></pre></tt></strike></i>

          Home / Wikipedia / leisure time

          leisure time


          leisure time

          author:comprehensive    Page View:41
          translucent 3D DNA helix with blue and purple background
          Adobe

          Verve Therapeutics said Monday that it had received clearance from the Food and Drug Administration to conduct a clinical trial in the U.S. of its experimental, gene-editing treatment for a common form of heart disease.

          The FDA’s action removes a clinical hold on Verve’s CRISPR-based therapy, called VERVE-101, that was placed on it last November. Verve now intends to recruit participants from U.S. sites into a Phase 1 study that’s been underway since last year in New Zealand and the United Kingdom.

          advertisement

          “We’re thrilled to get this clearance for VERVE-101,” said Verve CEO Sek Kathiresan. “Our study is called HEART-1 and our plan now is to activate U.S. sites.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In